Joint Formulary & PAD

Fluoxetine hydrochloride - Depression

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Capsules
Associated Icons :
Restrictions / Comments :
 

Status 2

Green (see narrative)
Formulations :
  • Dispersible tablets
  • Oral solution
Associated Icons :
Restrictions / Comments :
Important

Fluoxetine dispersible tablets are the more cost effective option in patents without dysphagia.

Fluoxetine oral solution and dispersible tablets are clinically interchangable for oral use.

 

Status 3

Non Formulary
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Fluoxetine hydrochloride
Indication :
Depression
Group Name :
Keywords :
SSRIs, selective serotonin re-uptake inhibitors, antidepressants
Brand Names Include :
Prozac
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Traffic Light Entries :
3

Other Indications

Below are listed other indications that Fluoxetine hydrochloride is used to treat.

  • No records returned.

Committee Recommendations (1)

GENERIC Fluoxetine has been considered by the PCN and has been assigned a GREEN traffic light status. NOTE - the branded product, Prozac, was considered BLACK at the PCN in May 2017. Note - The Mood Hive and associated local depression and anxiety treatment guidelines have been removed from PAD. Updated guidelines and resources for treating and managing depression in adults are being developed by Surrey & Borders Partnership. For current advice, in line with NICE guidance, please see the link to the Clinical Knowledge Summaries provided.